论文部分内容阅读
Ribociclib是一种选择性细胞周期蛋白依赖性激酶4/6抑制药,其可显著延长绝经后妇女雌激素受体阳性、人表皮生长因子受体2阴性的晚期或转移性乳腺癌患者的无进展生存期.美国食品药品监督管理局(FDA)采用加快审评的途径批准其上市,与芳香化酶抑制药联合使用作为以内分泌治疗为基础的初始方案,用于治疗绝经后女性雌激素受体阳性、人表皮生长因子受体2阴性的晚期或转移性乳腺癌.本文从Ribociclib的基本信息、药理作用、药代动力学、药效学、临床研究、药物相互作用、安全性、特殊人群用药等进行综述,旨在为其临床应用提供参考.“,”Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6,with significantly prolonged progression-free survival (PFS) in postmenopausal women with estrogen receptor-positive,human epidermal growth factor receptor-2 negative (ER +/HER2-) advanced or metastatic breast cancer.The US Food and Drug Administration (FDA) granted to accelerate the approval of ribociclib in combination with an aromatase inhibitor,as initial endocrine-based therapy for treatment of postmenopausal women with estrogen receptor-positive,human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.In this article,the properties,mechanism,pharmacokinetics,pharmacodynamics,clinical studies,drug interactions,safety,and use of ribociclib in specific populations were reviewed,aiming at providing references for its clinical applications.